329966-00-9

Upstream product

• 857390-29-5 3-(2,6-dimethoxyphenoxy)propane-1,2-diol 
• 91-10-1 1,3-dimethoxy-2-hydroxy-benzene 
• 57090-45-6 (2R)-3-chloro-1,2-propanediol 
• 329965-99-3 (2S)-3-(2,6-dimethoxyphenoxy)-1,2-propanediol acetonide 

Downstream Products

• 1106940-69-5 methanesulfonic acid (S)-3-(2,6-dimethoxyphenoxy)-2-methanesulfonyloxypropyl ester 
• 329966-02-1 (2S)-3-(2,6-dihydroxyphenoxy)-1,2-bis(tosyloxy)propane 
• 329966-04-3 (2R)-2-((tosyloxy)methyl)-5-methoxy-1,4-benzodioxane 
• 329966-03-2 (2R)-2-((tosyloxy)methyl)-5-hydroxy-1,4-benzodioxane 
• 329966-01-0 (2S)-3-(2,6-dimethoxyphenoxy)-1,2-bis(tosyloxy)propane 

Relevant academic research and scientific papers

Crystallization features and spontaneous resolution of 3-(2,6-dimethoxyphenoxy)propane-1,2-diol: The case of stable conglomerate and metastable solid solution

Phase behavior of 3-(2,6-dimethoxyphenoxy)propane-1,2-diol 1 was investigated by IR spectroscopy, X-ray diffraction, and DSC methods. Racemic diol 1 prone to spontaneous resolution and has been resolved into (S)- and (R)-enantiomers by a preferential crystallization procedure. Separation takes place, but it gives crystalline precipitates with moderate (60–70%) enantiomeric excess values. The plausible reason is the formation of metastable phase of solid solution during the crystallization.

2,3-DIHYDROBENZO[l,4] DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES

Compounds of formula (I), wherein X, Z, R1-R4, and m are as defined in the claims, exhibit alpha2C antagonistic activity and are thus useful for the treatment of diseases and conditions of the peripheric system and the central nervous system (CNS).